Navicixizumab Usage And Synthesis

Uses

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel.html" class="link-product" target="_blank"> Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3].

in vivo

References

[1] Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577. DOI:10.1200/JCO.21.01801
[2] Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705. DOI:10.21037/atm-20-4497
[3] Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2): C164.

Navicixizumab(1638338-43-8)Related Product Information

• Briakinumab
• Tozorakimab
• Rivabazumab
• Acapatamab
• Suptavumab
• Plonmarlimab
• Merpentan
• Ginisortamab
• Vepsitamab
• Barzolvolimab